Delhi Pharmaceutical Sciences and Research University Answered Questions

There are a total of 140 seats for the BPharm courses. Candidates are admitted as per the sanctioned intake and performance in the selection rounds. It is within the rights of the university to revise the seat count. The mentioned seat intake is as per the official website/ sanctioning body. It is still subject to changes and hence, is indicative. 

Delhi Pharmaceutical Sciences and Research University BPharm Ayurveda syllabus includes its core topics and related subjects. In the first semester, the students study basic concepts of the subject. Mentioned below are a few topics that are covered in the first semester:Environmental ScienceSanskritFundamentals of Ayurveda including SwasthavrittaFundamentals of Dravyaguna Vigyan-IFundamentals of Anatomy and Physiology, etc.

Yes, DPSRU offers a three-year BBA programme. It is a full-time course, which is divided into six semesters. The university offers the UG course in Healthcare. Admission to the programme is merit-based. Selection is done based on performance in Class 12 or equivalent examination. 

Delhi Pharmaceutical Sciences and Research University admit candidates on merit-basis. The aspirants of BBA programme are selected based on performance in Class 12 or equivalent examination. There is no entrance score requirements. However, the prescribed eligibility requirements must be fulfilled. 

In this course, the topics are related to the field of Ayurveda. Students get to learn the core subjects. With a industrial training included in the curriculum, the graduates become job ready. Mentioned below are some of the topics that are covered in the DPRSU BPharm in Ayurveda programme:Rasha ShastraFundamentals of Ayurveda including SwasthavrittaPharmaceutical BiologyPharmacologyHerbal Drug Technology, etc.

Both the universities offer BSc course across different specialisations. Delhi Pharmaceutical Sciences and Research University BSc tuition fee ranges from INR 19,000 to INR 1.8 lakh. Additionally, for BSc at DIT University, the tuition fees range from INR 1.8 Lacs to INR 6.5 lakh. As per this data, DPSRU offers more economical BSc programmes.However, it must be noted that the given fee details are as per the official website/ sanctioning body. It is still subject to changes and hence, is indicative.

There are nearly 544 MBA colleges in Delhi/ NCR. Delhi Pharmaceutical Sciences and Research University is one of the university in Delhi/ NCR that provides MBA in three specialisations. The total tuition fee for the PG-level course is INR 1.6 lakh. Mentioned below are a few colleges/ universities that offers an MBA in Delhi/ NCR:IIM RohtakGNIOT Institute of Management StudiesIndian Institute of Foreign TradeManagement Development Institute, etc.

Yes, Delhi Pharmaceutical Sciences and Research University offers two-year MBA courses. The PG-level programme is available in three specialisations, including Pharmaceutical Management, HHA, and International Trade and Management. Admission is granted based on merit in CUET-PG. Aspirants are advised to check out the eligibility requirements before applying for admission. 

In the first semester of DPSRU BBA course, the students study basics of Healthcare field. The course curriculum is designed in a way that the students become industry ready. Mentioned below are the topics covered in the first semester:Human Biology-IIntroduction to Community and Public HealthPrinciples of ManagementIntroduction to PharmacologyFundamentals of Epidemiology and BiostatisticsOrganisational BehaviourComputer Applications LabYoga Sciences

The total course fee is cumulative of multiple components. Students need to pay the course fee amount once the final selection is done. With fee and placements, the return on investment can be calculated. Table below showcases the DPSRU and Jamia Hamdard fee details:InstituteTotal Tuition FeeBPharm at DPSRUINR 2.4 lakhBPharm at Jamia HamdardINR 5.8 Lacs - INR 8.8 lakhNOTE: The given fee information is as per the official website/ sanctioning body. It is still subject to revision and hence, is indicative.